Osi Pharmaceuticals Inc. (OSIP) upgraded to Buy with price target $52 by Stanford Research
Stanford Research rated Buy Osi Pharmaceuticals Inc. (NASDAQ: OSIP) on 11/10/2008, when the stock price was $41.44. Since
then, Osi Pharmaceuticals Inc. has lost 25.05% as of 06/08/2010's recent price of $31.06. If you would have followed this Stanford Research's recommendation on OSIP, you would have lost 25.04% of your investment in 575 days.
OSI Pharmaceuticals, Inc. (OSI) is a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing unmet medical needs in oncology, diabetes and obesity. The Company's primary focus is oncology and its flagship product is Tarceva (erlotinib), a small molecule inhibitor of the epidermal growth factor receptor (EGFR). OSI also has research and development programs in diabetes and obesity, which are conducted through Prosidion Limited, the Company's United Kingdom subsidiary. Roche Holding Ltd. and OSI announced that Tarceva (erlotinib) has been approved in Japan for the treatment of patients with nonresectable, recurrent and advanced non-small cell lung cancer (NSCLC), which is aggravated following chemotherapy. In December 2008, the Company acquired from 7TM Pharma A/S, a number of early stage research assets and a G-Protein coupled receptor (GPCR), technology platform.
encompasses both institutional equity research and Washington-focused policy research, offering a perspective on individual companies, sector-specific topics and national policy.
The importance Stanford Group Company places on research comes from years of experience in a constantly changing world. We know that as markets develop and new sectors grow, it is imperative that our clients have the most accurate information available to ensure financial success. Stanford Group Company clients will always have our commitment to conduct informative and enlightening research.
As a part of our commitment to our clients, we provide objective, well-developed research. Our skilled analysts use their talent to provide invaluable research that can help in making important decisions. Thanks to a wide range of resources obtained through technology, experience and reputation, our research analysts develop reports on the most current firms and sectors. Our equity analysts offer insight and opinions on companies in the consumer/retail, media, energy, financial institutions, health care, technology and water/environment sectors.